ABBV Leads Its Peer Group. You Pay For That

AbbVie’s stock commands a king’s ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

Trading near $253 a share, AbbVie (ABBV) has outperformed the broader market over the last year, yet its stock sits in a peculiar spot among its pharmaceutical peers. Consider Pfizer (PFE), which trades at 18.3 times earnings while delivering a 25% operating margin. AbbVie, by contrast, trades at a huge 123.1 times GAAP earnings, backed by a superior operating margin of 33%. The performance is real, but so is the price tag.

AbbVie’s performance metrics lead the pack.

By the numbers, AbbVie’s position is clear. Its 33% operating margin and 9.5% revenue growth over the last twelve months both rank second in its competitive set, trailing only Eli Lilly’s (LLY) outlier performance. This operational strength has helped drive a +39% stock return over the past year, handily beating the S&P 500.

Yet that return only ranks fourth among its five closest peers, a sign that while the market acknowledges the quality, it may be hesitating at the price. Beyond simply being high, the company’s valuation metrics are the highest in the group, creating a stark mismatch between its operational rank and its cost to own.

The market is paying a premium for immunology dominance.

This premium is rooted in a powerful business story. AbbVie’s growth is fueled by its immunology franchise, particularly its two blockbuster drugs. On its latest call, management reported that Skyrizi sales surged to $4.5 billion, up 29%, while Rinvoq sales hit $2.1 billion, a 20% increase. This momentum led the company to raise its full-year earnings guidance.

The honest catch, however, is that the market sees the same thing investors do: a crowded and intensely competitive field. Analyst questions on the earnings call repeatedly probed the “broader I&I competitive landscape,” signaling concern that AbbVie’s leadership could be challenged by a wave of new therapies from rivals. The current valuation, therefore, reflects both today’s success and a bet that AbbVie can defend its turf, making the durability of its leadership a central question for investors.

The next generation of combination therapies will test the premium.

While AbbVie’s operational lead is earned, not accidental, its durability will be tested by what comes from its pipeline. The company aims to raise the standard of care with combination therapies, and management recently highlighted promising interim results from a key Crohn’s disease platform study. In that trial, a combination of Skyrizi and a novel antibody, ABBV-382, produced an endoscopic remission rate that was “double that of either monotherapy arm.” With the full study expected to be completed in the third quarter, the final data will be the clearest signal yet on whether AbbVie can innovate its way to justifying its premium price.

To keep score on this group beyond today, our full peer-by-peer dashboards for ABBV track the whole lineup, metric by metric.

Prefer the theme to this single name? a healthcare ETF like XLV owns the whole group. That way no single company’s next surprise decides the outcome.

Picking The Best Of The Group Still Leaves You In One Stock

Ranking a company against its peers sharpens the picture – but whichever name wins the comparison, owning too much of it is the same concentrated bet. Unwinding an oversized position the usual way means a tax bill. There is a way to protect the position and diversify out tax-efficiently.